Candidate tumor suppressor gene IRF6 is involved in human breast cancer pathogenesis via modulating PI3K-regulatory subunit PIK3R2 expression

References

• Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: good or bad news from the 2018 global cancer statistics? Cancer Commun (Lond). 2019;39(1):22. doi:10.1186/s40880-019-0368-631030667
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Podo F, Buydens LM, Degani H, et al. Triple negative breast cancer: present challenges and new perspectives. Mol Oncol. 2010;4:209–229. doi:10.1016/j.molonc.2010.04.00620537966
   PubMed Web of Science ®Google Scholar
• Cianfrocca M, Gradishar W. New molecular classifications of breast cancer. CA Cancer J Clin. 2009;59:303–313. doi:10.3322/caac.2002919729680
   PubMed Web of Science ®Google Scholar
• Karihtala P, Auvinen P, Kauppila S, Haapasaari KM, Jukkola-Vuorinen A, Soini Y. Vimentin, zeb1 and Sip1 are up-regulated in triple-negative and basal-like breast cancers: association with an aggressive tumour phenotype. Breast Cancer Res Treat. 2013;138:81–90.23412770
   PubMed Web of Science ®Google Scholar
• Gelmon K, Dent R, Mackey JR, Laing K, McLeod D, Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol. 2012;23:2223–2234. doi:10.1093/annonc/mds06722517820
   PubMed Web of Science ®Google Scholar
• Reeder-Hayes KE, Carey LA, Sikov WM. Clinical trials in triple negative breast cancer. Breast Dis. 2010;32:123–136. doi:10.3233/BD-2010-031021778571
   PubMedGoogle Scholar
• Toft DJ, Cryns VL. Minireview. Basal-like breast cancer: from molecular profiles to targeted therapies. Mol Endocrinol. 2011;25:199–211. doi:10.1210/me.2010-038920861225
   PubMedGoogle Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752. doi:10.1038/3502109310963602
   PubMed Web of Science ®Google Scholar
• Zuo T, Zeng H, Li H, et al. The influence of stage at diagnosis and molecular subtype on breast cancer patient survival: a hospital-based multi-center study. Chin J Cancer. 2017;36(1):84. doi:10.1186/s40880-017-0250-329070080
   PubMedGoogle Scholar
• Botti E, Spallone G, Moretti F, et al. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas. Proc Natl Acad Sci USA. 2011;108:13710–13715. doi:10.1073/pnas.111093110821807998
   PubMed Web of Science ®Google Scholar
• Savitsky D, Tamura T, Yanai H, Taniguchi T. Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother. 2010;59:489–510. doi:10.1007/s00262-009-0804-620049431
   PubMed Web of Science ®Google Scholar
• Ingraham CR, Kinoshita A, Kondo S, et al. Abnormal skin, limb and craniofacial morphogenesis in mice deficient for interferon regulatory factor 6 (Irf6). Nat Genet. 2006;38:1335–1340. doi:10.1038/ng190317041601
   PubMed Web of Science ®Google Scholar
• Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol. 2001;19:623–655. doi:10.1146/annurev.immunol.19.1.62311244049
   PubMed Web of Science ®Google Scholar
• Richardson RJ, Dixon J, Malhotra S, et al. Irf6 is a key determinant of the keratinocyte proliferation-differentiation switch. Nat Genet. 2006;38:1329–1334. doi:10.1038/ng189417041603
   PubMed Web of Science ®Google Scholar
• Richardson RJ, Hammond NL, Coulombe PA, et al. Periderm prevents pathological epithelial adhesions during embryogenesis. J Clin Invest. 2014;124:3891–3900. doi:10.1172/JCI7194625133425
   PubMed Web of Science ®Google Scholar
• Kondo S, Schutte BC, Richardson RJ, et al. Mutations in IRF6 cause Van der Woude and popliteal pterygium syndromes. Nat Genet. 2002;32:285–289. doi:10.1038/ng98512219090
   PubMed Web of Science ®Google Scholar
• Little HJ, Rorick NK, Su LI, et al. Missense mutations that cause Van der Woude syndrome and popliteal pterygium syndrome affect the DNA-binding and transcriptional activation functions of IRF6. Hum Mol Genet. 2009;18:535–545. doi:10.1093/hmg/ddn38119036739
   PubMed Web of Science ®Google Scholar
• Richardson RJ, Dixon J, Jiang R, Dixon MJ. Integration of IRF6 and Jagged2 signalling is essential for controlling palatal adhesion and fusion competence. Hum Mol Genet. 2009;18:2632–2642. doi:10.1093/hmg/ddp20119439425
   PubMed Web of Science ®Google Scholar
• Bailey CM, Abbott DE, Margaryan NV, Khalkhali-Ellis Z, Hendrix MJ. Interferon regulatory factor 6 promotes cell cycle arrest and is regulated by the proteasome in a cell cycle-dependent manner. Mol Cell Biol. 2008;28:2235–2243. doi:10.1128/MCB.01866-0718212048
   PubMed Web of Science ®Google Scholar
• Ferretti E, Li B, Zewdu R, et al. A conserved Pbx-Wnt-p63-Irf6 regulatory module controls face morphogenesis by promoting epithelial apoptosis. Dev Cell. 2011;21:627–641. doi:10.1016/j.devcel.2011.08.00521982646
   PubMed Web of Science ®Google Scholar
• Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–6091. doi:10.1158/0008-5472.CAN-07-685418676830
   PubMed Web of Science ®Google Scholar
• Karlsson E, Pérez-Tenorio G, Amin R, et al. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials. Breast Cancer Res. 2013;15:R96. doi:10.1186/bcr355724131622
   PubMed Web of Science ®Google Scholar
• Chandarlapaty S, Sakr RA, Giri D, et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res. 2012;18:6784–6791. doi:10.1158/1078-0432.CCR-12-178523092874
   PubMed Web of Science ®Google Scholar
• Barone I, Cui Y, Herynk MH, et al. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. Cancer Res. 2009;69:4724–4732. doi:10.1158/0008-5472.CAN-08-366019487288
   PubMed Web of Science ®Google Scholar
• Razis E, Bobos M, Kotoula V, et al. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer. Breast Cancer Res Treat. 2011;128:447–456. doi:10.1007/s10549-011-1572-521594665
   PubMed Web of Science ®Google Scholar
• Park SW, Zhou Y, Lee J, et al. The regulatory subunits of PI3K, p85α and p85β, interact with XBP-1 and increase its nuclear translocation. Nat Med. 2010;16:429–437. doi:10.1038/nm.209920348926
   PubMed Web of Science ®Google Scholar
• Ito Y, Hart JR, Ueno L, Vogt PK. Oncogenic activity of the regulatory subunit p85beta of phosphatidylinositol 3-kinase (PI3K). Proc Natl Acad Sci USA. 2014;111:16826–16829. doi:10.1073/pnas.142028111125385636
   PubMed Web of Science ®Google Scholar
• Hale BG, Jackson D, Chen YH, Lamb RA, Randall RE. Influenza A virus NS1 protein binds p85beta and activates phosphatidylinositol-3-kinase signaling. Proc Natl Acad Sci USA. 2006;103:14194–14199. doi:10.1073/pnas.060610910316963558
   PubMed Web of Science ®Google Scholar
• Li W, Wang G, Zhang H, et al. Inability of NS1 protein from an H5N1 influenza virus to activate PI3K/Akt signaling pathway correlates to the enhanced virus replication upon PI3K inhibition. Vet Res. 2012;43:36. doi:10.1186/1297-9716-43-3622530768
   PubMed Web of Science ®Google Scholar
• Xu L, Huang TJ, Hu H, et al. The developmental transcription factor IRF6 attenuates ABCG2 gene expression and distinctively reverses stemness phenotype in nasoparyngeal carcinoma. Cancer Lett 2018;431:230–243. doi:10.1016/j.canlet.2017.10.016
   Google Scholar
• Slattery ML, Lundgreen A, Bondurant KL, Wolff RK. Interferon-signaling pathway: associations with colon and rectal cancer risk and subsequent survival. Carcinogenesis. 2011;32:1660–1667. doi:10.1093/carcin/bgr18921859832
   PubMed Web of Science ®Google Scholar
• Bailey CM, Khalkhali-Ellis Z, Kondo S, et al. Mammary serine protease inhibitor (Maspin) binds directly to interferon regulatory factor 6: identification of a novel serpin partnership. J Biol Chem. 2005;280:34210–34217. doi:10.1074/jbc.M50352320016049006
   PubMed Web of Science ®Google Scholar
• Zengin T, Ekinci B, Kucukkose C, Yalcin-Ozuysal O. IRF6 is involved in the regulation of cell proliferation and transformation in MCF10A cells downstream of notch signaling. PLoS One. 2015;10:e0132757. doi:10.1371/journal.pone.013275726161746
   PubMed Web of Science ®Google Scholar
• Bailey CM, Margaryan NV, Abbott DE, et al. Temporal and spatial expression patterns for the tumor suppressor Maspin and its binding partner interferon regulatory factor 6 during breast development. Dev Growth Differ. 2009;51:473–481. doi:10.1111/j.1440-169X.2009.01110.x19527266
   PubMed Web of Science ®Google Scholar
• Subik K, Lee JF, Baxter L, et al. The expression patterns of eR, pR, HeR2, cK5/6, eGFR, Ki-67 and AR by Immunohistochemical analysis in breast cancer cell lines. Breast Cancer. 2010;4:35–41.20697531
   PubMedGoogle Scholar
• Xie P, Yang J-P, Cao Y, et al. Promoting tumorigenesis in nasopharyngeal carcinoma, NEDD8 serves as a potential theranostic target. Cell Death Dis. 2017;8(6):e2834. doi:10.1038/cddis.2017.51828569775
   PubMedGoogle Scholar
• Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc. 2012;7:562–578. doi:10.1038/nprot.2012.01622383036
   PubMed Web of Science ®Google Scholar
• Xie C, Mao X, Huang J, et al. KOBAS 2.0: a web server for annotation and identification of enriched pathways and diseases. Nucleic Acids Res. 2011;39(Web Server issue):W316–W322. doi:10.1093/nar/gkr48321715386
   PubMedGoogle Scholar
• Croker AK, Goodale D, Chu J, et al. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009;13:2236–2252. doi:10.1111/j.1582-4934.2008.00455.x18681906
   PubMed Web of Science ®Google Scholar
• He K, Wang X, Guan X, et al. Vinorelbine plus gemcitabine or cisplatin as first-line treatment of HER2-negative advanced breast cancer. Anticancer Res. 2017;37:5647–5653. doi:10.21873/anticanres.1200028982882
   PubMed Web of Science ®Google Scholar
• Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–1657. doi:10.1126/science.296.5573.165512040186
   PubMed Web of Science ®Google Scholar
• Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI. Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt. Cancer Res. 2004;64:4394–4399. doi:10.1158/0008-5472.CAN-04-034315231645
   PubMed Web of Science ®Google Scholar
• Tamura T, Yanai H, Savitsky D, Taniguchi T. The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol. 2008;26:535–584. doi:10.1146/annurev.immunol.26.021607.09040018303999
   PubMed Web of Science ®Google Scholar
• Eroshkin A, Mushegian A. Conserved transactivation domain shared by interferon regulatory factors and Smad morphogens. J Mol Med (Berl). 1999;77(5):403–405.10426188
   PubMed Web of Science ®Google Scholar
• Qin BY, Liu C, Lam SS, et al. Crystal structure of IRF-3 reveals mechanism of autoinhibition and virus-induced phosphoactivation. Nat Struct Biol. 2003;10(11):913–921. doi:10.1038/nsb100214555996
   PubMedGoogle Scholar
• Kwa MQ, Huynh J, Aw J, et al. Receptor-interacting protein kinase 4 and interferon regulatory factor 6 function as a signaling axis to regulate keratinocyte differentiation. J Biol Chem. 2014;289(45):31077–31087. doi:10.1074/jbc.M114.58938225246526
   PubMed Web of Science ®Google Scholar
• de Lima RL, Hoper SA, Ghassibe M, et al. Prevalence and nonrandom distribution of exonic mutations in interferon regulatory factor 6 in 307 families with Van der Woude syndrome and 37 families with popliteal pterygium syndrome. Genet Med. 2009;11(4):241–247. doi:10.1097/GIM.0b013e318197a49a19282774
   PubMed Web of Science ®Google Scholar
• Qian CN, Furge KA, Knol J, et al. Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res. 2009;69:8256–8264. doi:10.1158/0008-5472.CAN-09-168919843858
   PubMed Web of Science ®Google Scholar
• Cortés I, Sánchez-Ruíz J, Zuluaga S, et al. p85β phosphoinositide 3-kinase subunit regulates tumor progression. Pnas. 2012;109(28):11318–11323. doi:10.1073/pnas.111813810922733740
   PubMed Web of Science ®Google Scholar
• Alcázar I, Cortés I, Zaballos A, et al. p85β phosphoinositide 3-kinase regulates CD28 coreceptor function. Blood. 2009;113:3198–3208. doi:10.1182/blood-2008-04-15294219190244
   PubMed Web of Science ®Google Scholar